Last €5.41 EUR
Change Today +0.282 / 5.50%
Volume 0.0
MXE On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 1:54 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

mimedx group inc (MXE) Snapshot

Open
€5.32
Previous Close
€5.13
Day High
€5.41
Day Low
€5.22
52 Week High
12/19/13 - €6.40
52 Week Low
09/24/13 - €2.68
Market Cap
572.0M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
105.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MIMEDX GROUP INC (MXE)

Related News

No related news articles were found.

mimedx group inc (MXE) Related Businessweek News

No Related Businessweek News Found

mimedx group inc (MXE) Details

MiMedx Group, Inc., together with its subsidiaries, designs, manufactures, and markets products and tissue processing services in the United States. The company’s products include patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies comprise AmnioFix and EpiFix, which are tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through the company’s donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. It processes the human amniotic membrane utilizing its proprietary PURION process to produce a safe and effective implant. The company also provides CollaFix, a medical device technology platform. It supplies amniotic tissue on OEM basis for application in the wound care, surgical, sports medicine, ophthalmic, and dental sectors of healthcare through direct sales force, independent sales representatives, and distributors, as well as through private label or OEM relationships. The company is headquartered in Marietta, Georgia.

222 Employees
Last Reported Date: 03/4/14

mimedx group inc (MXE) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $465.2K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $385.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $268.3K
Vice President, General Counsel and Consultan...
Total Annual Compensation: $240.0K
Compensation as of Fiscal Year 2013.

mimedx group inc (MXE) Key Developments

MiMedx Group, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter and Full Year of 2014

MiMedx Group, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. The company recorded record revenue for the second quarter of 2014 of $25.6 million, a $12.1 million of 89% increase over 2013 second quarter revenue of $13.5 million, and above its latest guidance range of $24 million to $25 million. The company's gross margins for the quarter ended June 30, 2014 were 89% as compared to 84% in the second quarter of 2013. Earnings before interest, taxes, depreciation, amortization, share-based compensation (adjusted EBITDA) for the quarter ended June 30, 2014 were $2.9 million, a $1.7 million or 148% improvement, as compared to the adjusted EBITDA of $1.2 million for the second quarter of 2013. Net loss for the second quarter of 2014 was $0.4 million or $0.00 per diluted common share, as compared to net loss of $0.8 million, or $0.01 per diluted common share, in the prior year second quarter. Cash flow from operating activities for the quarter ended June 30, 2014 was a positive $1.2 million, due primarily to improved operating results and a significant improvement in its Days' Sales Outstanding in accounts receivable, as compared to a negative $0.8 million in the second quarter of 2013. Operating loss was $391,763 against $744,217 a year ago. Loss before income tax provision was $400,192 against $757,389 a year ago. Net cash inflows from operating activities were $1,179,220 against net cash out flows from operating activities of $755,362 a year ago. Purchases of equipment were $679,583 against $979,396 a year ago. For the six months ended June 30, 2014, the company recorded record revenue of $45.1 million, a $20.1 million or 80% increase over revenue of $25.1 million for the first six months of 2013. The company's gross margins for the six months ended June 30, 2014 were 87% as compared to 84% in the same period of 2013. Adjusted EBITDA for the six months ended June 30, 2014, were $4.9 million, a $2.6 million or 113% improvement, as compared to the adjusted EBITDA of $2.3 million for the first half of 2013. Net loss for the six months ended June 30, 2014 was $1.3 million, as compared to the net loss of $2.4 million in the prior year same period. Operating loss was $1,282,778 against $971,107 a year ago. Loss before income tax provision was $1,312,231 against $2,327,522 a year ago. Net cash inflows from operating activities were $431,751 against $2,853,548 a year ago. Purchases of equipment were $1,145,351 against $1,052,930 a year ago. The company provided earnings guidance for the third quarter and full year of 2014. For the third quarter of 2014, the company expects revenue to be in the range of $30 million to $32 million. the company also expects to record an operating profit for the third quarter of 2014. The company has increased its previously published guidance for full year 2014, and now expects revenue to be in the range of $110 million to $115 million for full year 2014.

MiMedx Group, Inc. Files Initial Investigational New Drug Application

MiMedx Group, Inc. announced it has filed its initial Investigational New Drug (IND) application with the Food and Drug Administration (FDA). The IND submission, which was filed on July 22, 2014, is the Company's initial submission for certain indications of its micronized allografts towards targeted Biologics License Applications (BLAs).

MiMedx Group, Inc., Q2 2014 Earnings Call, Jul 29, 2014

MiMedx Group, Inc., Q2 2014 Earnings Call, Jul 29, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MXE:GR €5.41 EUR +0.282

MXE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Shire PLC 4,923 GBp +36.00
View Industry Companies
 

Industry Analysis

MXE

Industry Average

Valuation MXE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.4x
Price/Book 9.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MIMEDX GROUP INC, please visit www.mimedx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.